Summary:
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous administration of TEV-48125 in adult patients with chronic migraine or episodic migraine
Qualified Participants Must:
• Be 18-70 years old
•
Have a history of migraines
Qualified Participants May Receive:
Qualified participants may recieve investigational medication or placebo, will receive compensation for time and travel.